Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Final Data for Pancreatic

<< Previous

Bullboard Posts

Next >>

Post by JohnnyYegon Apr 29, 2021 5:40pm

417 Views

Post# 33098273

Final Data for Pancreatic

So the final data for the NU 18I01 "Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer" is being presented at ASCO in June. Not a simple press release - but a presentation at ASCO. Interesting. Something compelling to present? https://www.clinicaltrials.gov/ct2/show/NCT03723915?term=Pelareorep%3B+reolysin&draw=2&rank=1

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec